AU2015358910B2 - Novel method of use - Google Patents

Novel method of use Download PDF

Info

Publication number
AU2015358910B2
AU2015358910B2 AU2015358910A AU2015358910A AU2015358910B2 AU 2015358910 B2 AU2015358910 B2 AU 2015358910B2 AU 2015358910 A AU2015358910 A AU 2015358910A AU 2015358910 A AU2015358910 A AU 2015358910A AU 2015358910 B2 AU2015358910 B2 AU 2015358910B2
Authority
AU
Australia
Prior art keywords
compound
isopropyl
pharmaceutically acceptable
acne
dihydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015358910A
Other languages
English (en)
Other versions
AU2015358910A1 (en
Inventor
Javier Cote-Sierra
Steven M. Frey
Susan H. Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dermavant Sciences GmbH
Original Assignee
Dermavant Sciences GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dermavant Sciences GmbH filed Critical Dermavant Sciences GmbH
Publication of AU2015358910A1 publication Critical patent/AU2015358910A1/en
Assigned to Dermavant Sciences GmbH reassignment Dermavant Sciences GmbH Request for Assignment Assignors: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Application granted granted Critical
Publication of AU2015358910B2 publication Critical patent/AU2015358910B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2015358910A 2014-12-12 2015-12-09 Novel method of use Active AU2015358910B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462090908P 2014-12-12 2014-12-12
US62/090,908 2014-12-12
PCT/IB2015/059490 WO2016092493A1 (en) 2014-12-12 2015-12-09 Novel method of use

Publications (2)

Publication Number Publication Date
AU2015358910A1 AU2015358910A1 (en) 2017-06-29
AU2015358910B2 true AU2015358910B2 (en) 2019-01-24

Family

ID=55025296

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015358910A Active AU2015358910B2 (en) 2014-12-12 2015-12-09 Novel method of use

Country Status (11)

Country Link
US (1) US10376475B2 (enExample)
EP (1) EP3229840B1 (enExample)
JP (3) JP7313117B2 (enExample)
KR (1) KR102607222B1 (enExample)
AR (1) AR102973A1 (enExample)
AU (1) AU2015358910B2 (enExample)
CA (1) CA2970739C (enExample)
DK (1) DK3229840T5 (enExample)
ES (1) ES2829637T3 (enExample)
TW (1) TWI692357B (enExample)
WO (1) WO2016092493A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3297605B1 (en) 2015-05-21 2022-05-04 Dermavant Sciences GmbH Topical pharmaceutical compositions
US11617724B2 (en) 2015-05-21 2023-04-04 Dermavant Sciences GmbH Topical pharmaceutical compositions
US20170231922A1 (en) * 2016-02-16 2017-08-17 Horizon GenoMed Therapeutics, Inc 3, 5-dihydroxy-4-isopropylstilbene (dhis) as miticidal agent and its therapeutic uses
JP6912664B2 (ja) 2017-11-10 2021-08-04 ダーマヴァント サイエンシーズ ゲーエムベーハー タピナロフを調製するためのプロセス
US10967197B2 (en) 2018-08-29 2021-04-06 Azulite, Inc. Phototherapy devices and methods for treating truncal acne and scars
US11497718B2 (en) 2018-11-13 2022-11-15 Dermavant Sciences GmbH Use of tapinarof for the treatment of atopic dermatitis
US20220054467A1 (en) * 2019-02-25 2022-02-24 Sol-Gel Technologies Ltd. Treatment of psoriasis with topical tapinarof-tazarotene combination compositions
WO2020194313A1 (en) * 2019-03-26 2020-10-01 Sol-Gel Technologies Ltd. Treatment of hidradenitis suppurativa with tapinarof compositions
US20220287990A1 (en) * 2019-07-24 2022-09-15 Sol-Gel Technologies Ltd. Topical jak inhibitor combination compositions for treatment of inflammatory skin conditions
US20220331268A1 (en) * 2019-09-26 2022-10-20 Sol-Gel Technologies Ltd. Treatment of skin disorders with topical combination compositions comprising tapinarof and an additional ahr activator
JP2023503132A (ja) * 2019-11-24 2023-01-26 ソル － ゲル テクノロジーズ リミテッド タピナロフおよびｐｄｅ４阻害剤を含む局所用組成物による皮膚障害の治療
CN116265421B (zh) * 2021-12-17 2024-01-02 上海泽德曼医药科技有限公司 用于预防或治疗中枢神经系统相关疾病的化合物
WO2023109859A1 (zh) * 2021-12-15 2023-06-22 上海泽德曼医药科技有限公司 二苯乙烯类化合物及其在用于预防和/或治疗中枢神经系统相关疾病中的应用
JP2025529076A (ja) * 2022-08-30 2025-09-04 ダーマヴァント サイエンシーズ ゲーエムベーハー ＡｈＲ媒介疾患の治療に使用するタピナロおよびそのアナログ製剤

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050059733A1 (en) * 1999-12-06 2005-03-17 Welichem Biotech, Inc. Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7513994A (en) 1993-07-27 1995-02-28 Agro-Biotech Corporation Novel fungicidal properties of metabolites, culture broth, stilbene derivatives and indole derivatives produced by the bacteria (xenorhabdus) and (photorhabdus) spp.
US5747482A (en) * 1996-07-30 1998-05-05 Bernstein; Lawrence R. Methods and compositions to inhibit keratinocyte proliferation
DE60043120D1 (de) 1999-12-06 2009-11-19 Welichem Biotech Inc Polyhydroxystilbene und -stilbenoxide als antipsoriasismittel und proteinkinasehemmer
JP2006508930A (ja) * 2002-10-01 2006-03-16 ウェリケム バイオテック インコーポレーテッド 新規生物活性ジフェニルエテン化合物およびその治療への適用
FR2917427B1 (fr) * 2007-06-18 2009-08-21 Galderma Res & Dev Inhibiteurs de tace dans le traitement de l'acne
WO2009108762A2 (en) * 2008-02-26 2009-09-03 The Penn State Research Foundation Methods and compositions for treatment of retinoid-responsive conditions
US20100003315A1 (en) * 2008-07-02 2010-01-07 Willeford Kenneth L Method and Composition for the Treatment of Skin Conditions
CN101531571B (zh) 2009-04-17 2013-03-20 河北科技大学 六次甲基四胺氧化合成二苯乙烯类化合物的方法
CN101633606B (zh) 2009-08-13 2014-08-27 河北科技大学 盐酸非均相氯代合成茋类化合物的方法
CN101648851B (zh) 2009-09-03 2012-10-10 河北科技大学 (e)-3,5-二羟基-4-异丙基二苯乙烯的清洁制备方法
CN101830764A (zh) 2010-05-05 2010-09-15 河北科技大学 利用Pfitzner-moffatt氧化反应合成茋类化合物的方法
CN101838173A (zh) 2010-05-07 2010-09-22 河北科技大学 利用Kornblum氧化反应合成茋类化合物的方法
AU2012277951C1 (en) * 2011-06-27 2019-02-21 Galderma Research & Development New Th17 differentiation markers for acne and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050059733A1 (en) * 1999-12-06 2005-03-17 Welichem Biotech, Inc. Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HANNA-LEENA KELHÄLÄ ET AL, "IL-17/Th17 Pathway Is Activated in Acne Lesions", PLOS ONE, (2014-08-25), vol. 9, no. 8, doi:10.1371/journal.pone.0105238, page e105238. *

Also Published As

Publication number Publication date
AR102973A1 (es) 2017-04-05
DK3229840T3 (da) 2020-11-09
US20170360719A1 (en) 2017-12-21
WO2016092493A1 (en) 2016-06-16
ES2829637T3 (es) 2021-06-01
US10376475B2 (en) 2019-08-13
JP2017537936A (ja) 2017-12-21
JP2021152018A (ja) 2021-09-30
CA2970739C (en) 2023-10-03
KR102607222B1 (ko) 2023-11-29
TWI692357B (zh) 2020-05-01
EP3229840A1 (en) 2017-10-18
DK3229840T5 (da) 2020-11-16
EP3229840B1 (en) 2020-09-09
JP7313117B2 (ja) 2023-07-24
JP2023123554A (ja) 2023-09-05
TW201639548A (zh) 2016-11-16
AU2015358910A1 (en) 2017-06-29
KR20170095928A (ko) 2017-08-23
CA2970739A1 (en) 2016-06-16

Similar Documents

Publication Publication Date Title
AU2015358910B2 (en) Novel method of use
Han et al. The antimicrobial effect of CEN1HC-Br against Propionibacterium acnes and its therapeutic and anti-inflammatory effects on acne vulgaris
US20220273595A1 (en) Compositions and methods for treating eczema
Lee et al. Protease-activated receptor-2 mediates the expression of inflammatory cytokines, antimicrobial peptides, and matrix metalloproteinases in keratinocytes in response to Propionibacterium acnes
JP6944399B2 (ja) プロバイオティクス細菌
Bitschar et al. Staphylococcus aureus skin colonization is enhanced by the interaction of neutrophil extracellular traps with keratinocytes
EP2379085B1 (en) Pharmaceutical preparation comprising supernatant of blood mononuclear cell culture
GB2542797A (en) Use of cannabinoids in the treatment of inflammatory skin diseases
Wang et al. Thymol activates TRPM8-mediated Ca2+ influx for its antipruritic effects and alleviates inflammatory response in Imiquimod-induced mice
AU2024202737A1 (en) Therapeutic method
AU2018260096B2 (en) Rucaparib, Talazoparib, Veliparib, Olaparib and AZD 2461 for treating impaired skin wound healing
Yoon et al. Topical glucocorticoid or pimecrolimus treatment suppresses thymic stromal lymphopoietin-related allergic inflammatory mechanism in an oxazolone-induced atopic dermatitis murine model
Brito et al. Cytotoxicity and potential anti-inflammatory activity of velutin on RAW 264.7 cell line differentiation: Implications in periodontal bone loss
Xie et al. AR-A014418, a glycogen synthase kinase-3β inhibitor, mitigates lipopolysaccharide-induced inflammation in rat dental pulp stem cells via NLR family pyrin domain containing 3 inflammasome impairment
WO2012105706A1 (ja) ケロイド治療剤
US20220118020A1 (en) Pharmaceutical preparation comprising supernatant of blood mononuclear cell culture and method of use
TW201711696A (zh) 用於促進傷口癒合的吳郭魚抗菌胜肽
Tran Effect of Oxyresveratrol on Inflammatory Skin Diseases||
WO2025111413A1 (en) Treatment for skin disorders
Helwa The Mechanism of monomethylfumarate as an anti-psoriatic agent

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: DERMAVANT SCIENCES GMBH

Free format text: FORMER APPLICANT(S): GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED

FGA Letters patent sealed or granted (standard patent)